An Italy-based KOL gives their insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CML. Topics discussed include treatment strategies for chronic-phase and blast-phase patients, and the potential of novel TKI vodobatinib in the treatment of CML. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.